Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

6.3%

1 terminated/withdrawn out of 16 trials

Success Rate

91.7%

+5.2% vs industry average

Late-Stage Pipeline

25%

4 trials in Phase 3/4

Results Transparency

27%

3 of 11 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

9(60.0%)

Phase 1

2(13.3%)

Phase 4

2(13.3%)

Phase 3

2(13.3%)

15Total

Phase 2(9)

Phase 1(2)

Phase 4(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT06958796Phase 4Recruiting

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Role: collaborator

NCT04204252Phase 3Recruiting

Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"

Role: lead

NCT07009548Phase 4Enrolling By Invitation

CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients

Role: collaborator

NCT02040090Phase 2Completed

Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

Role: lead

NCT02912845Phase 3Completed

Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies

Role: lead

NCT02614872Phase 2Completed

Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

Role: lead

NCT02956122Phase 2Terminated

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

Role: collaborator

NCT04550325Phase 1Completed

Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19

Role: lead

NCT03172455Unknown

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

Role: collaborator

NCT02001688Phase 2Completed

Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

Role: lead

NCT01217671Phase 2Completed

International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema

Role: lead

NCT02005848Phase 2Completed

Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

Role: lead

NCT01661192Phase 2Completed

Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes

Role: collaborator

NCT01304537Phase 1Completed

Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus

Role: lead

NCT00499837Phase 2Completed

Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients

Role: lead

NCT00460096Phase 2Completed

Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency

Role: lead

All 16 trials loaded